Business Wire

PACE-TELEMATICS

31.7.2024 14:01:33 CEST | Business Wire | Press release

Share
Europe’s Largest Gas Station Network: PACE Telematics Surpasses the 10,000 Mark

PACE Telematics, a leading provider of mobile payment solutions in the European gas station market, is proud to announce a significant milestone: The company now enables mobile payments at over 10,000 gas stations in 15 European countries. Renowned brands such as Esso, JET, OMV, and TAMOIL are among its gas station partners. By integrating with PACE's Connected Fueling platform, they are part of Europe's largest digital gas station network. This achievement positions PACE as Europe’s market leader and highlights the growing importance of mobile payment solutions in the gas station sector.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240731147479/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

PACE Telematics Surpasses the 10,000 Mark and Becomes Europe’s Largest Gas Station Network. (Graphic: Business Wire)

An increasing number of consumers are using their smartphones, wearables, or in-car applications for payments. This has been highlighted by the fifth edition of the Visa Payment Monitor 2023 in collaboration with the opinion research institute forsa. According to a representative online survey of 1,700 people in Germany, nearly one in four people (23 percent) pay with their mobile phone or wearables, such as smartwatches, compared to only six percent four years ago – indicating that mobile payments are gaining momentum. Reasons for this development include the growing implementation and acceptance of mobile payment technologies, as well as the convenience and efficiency they offer. According to an analysis by the Boston Consulting Group, the European leaders in mobile payments are Norway, Denmark, and Luxembourg.

PACE Becomes Europe's Largest Gas Station Network

The trend is also clearly noticeable in the gas station business: PACE's network, which enables mobile payments via app, wearable, or vehicle directly at the pump through the Connected Fueling platform, is the first provider to surpass the 10,000 mark. PACE has become the largest gas station network in Europe, spanning a total of 15 European countries. Renowned brands such as Esso, JET, OMV, TAMOIL and many more are among the partners. At these stations, mobile payments are now used by over 1.3 million users.

Connected Fueling Platform Offers Numerous Advantages

The Connected Fueling platform by PACE offers numerous advantages to gas station operators, fuel card issuers, app providers, and automotive manufacturers by enabling mobile payments at the pump. These advantages include increased convenience through digital receipts and mobile payments, faster payment processing, and improved service in the shop due to shorter waiting times and reduced workloads for employees.

The connection to the platform is technically uncomplicated for gas station partners. To ensure smooth communication, the respective POS system is connected to the PACE Connected Fueling platform. The PACE interface "Open Fueling Site Connect" (OpenFSC) is a free open-source API used by most connected industry partners, such as Ratio Elektronik, to quickly and easily connect to the Connected Fueling platform. PACE already has numerous existing integrations with various POS system providers such as Fortech, Scheidt & Bachmann or TSG Deutschland and many more.

Plug-and-Play Solution: Maximizing Business Success in Europe

The Connected Fueling platform offers an innovative plug-and-play solution that enables gas stations, fuel and fleet card providers, mobility apps, and car manufacturers to comprehensively digitize and establish presence in the European market. While previous integration projects and multi-million investments were necessary for plastic fuel cards to enter the European market, fuel card partners can now operate quickly and efficiently across Europe with just one integration into the platform. More and more fuel card issuers such as DKV, Esso, Hoyer, or LOGPAY are taking advantage of these benefits.

Furthermore, additional mobility use cases are on the roadmap based on the technical foundation of the platform, which will expand the offering in the near future, including, for example, mobile car wash payments.

About PACE Telematics & Connected Fueling

The open Connected Fueling platform, operated by PACE Telematics (Karlsruhe, Germany), enables seamless mobile payment directly at the fuel pump through a uniform, cost-saving integration of all partners with the Connected Fueling cloud system. The independent platform is open to all petroleum companies, service station operators, fuel card issuers and POS system providers. Additionally, the platform offers automobile manufacturers and app developers flexible interfaces and easily integrable Software Development Kits (SDKs) to incorporate the mobile payment functionality into their systems. For more information, please visit www.connectedfueling.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240731147479/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye